First randomized controlled trial shows promise of a ketogenic diet in psychotic disorders

Published contiguous successful Schizophrenia Bulletin, a first-of-its-kind randomized controlled proceedings (RCT) from researchers astatine the University of California, San Francisco (UCSF), adds to increasing lit connected the imaginable payment of a ketogenic fare for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum oregon bipolar 1 disorders, demonstrated accelerated metabolic improvements with a ketogenic fare compared with diet-as-usual during an archetypal one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic fare hold saw meaningful gains crossed metabolic, psychiatric and cognitive measures.